Elsevier

The Lancet Neurology

Volume 6, Issue 7, July 2007, Pages 652-662
The Lancet Neurology

Personal View
Deciphering the role of heterozygous mutations in genes associated with parkinsonism

https://doi.org/10.1016/S1474-4422(07)70174-6Get rights and content

Summary

The association of six genes with monogenic forms of parkinsonism has unambiguously established that the disease has a genetic component. Of these six genes, LRRK2 (leucine-rich repeat kinase 2, or PARK8), parkin (PARK2), and PINK1 (PTEN-induced putative kinase 1, or PARK6) are the most clinically relevant because of their mutation frequency. Insights from initial familial studies suggest that LRRK2-associated parkinsonism is dominantly inherited, whereas parkinsonism linked to parkin or PINK1 is recessive. However, screening of patient cohorts has revealed that up to 70% of people heterozygous for LRRK2 mutations are unaffected, and that more than 50% of patients with mutations in parkin or PINK1 have only a single heterozygous mutation. Deciphering the role of heterozygosity in parkinsonism is important for the development of guidelines for genetic testing, for the counselling of mutation carriers, and for the understanding of late-onset Parkinson's disease. We discuss the roles of heterozygous LRRK2 mutations and heterozygous parkin and PINK1 mutations in the development of parkinsonism, and propose an integrated aetiological model for this complex disease.

Introduction

Identification of several monogenic forms has established that parkinsonism is a multifactorial disorder that has an unambiguous genetic cause in a subset of patients. Genetic mutations can be detected in about 3% of patients with parkinsonism,1 but the proportion can be as high as 77% in groups of patients selected for age at onset, positive family history,2 and ethnic origin.3, 4 Inheritance of the most common familial forms of parkinsonism is thought to be autosomal dominant in the case of LRRK2 (leucine-rich repeat kinase 2; also known as PARK8) or recessive in the cases of parkin (also known as PARK2) and PINK1 (PTEN-induced putative kinase 1; also known as PARK6). However, in 2000, researchers began to question the simple applicability of these established mendelian concepts to the inheritance of parkinsonism.2 At that time, experience from large studies that screened for mutations in recessively inherited parkin first revealed that more than half of the affected patients had only one mutated allele (rather than the expected two). Similar observations were later reported for PINK1. Conversely, most people carrying a single mutation in the dominantly transmitted LRRK2 gene are clinically unaffected. In this article we discuss the role of heterozygous LRRK2 mutations in the development of parkinsonism and provide the first review of the debated role of heterozygous mutations in the putative recessive genes parkin and PINK1. We have taken into account results from mutation analyses in patients, family members, and controls, and findings from clinical, neuroimaging, and electrophysiological studies in mutation carriers. We have integrated these findings into a hypothetical model of parkinsonism as a complex disorder. We also discuss the implications of heterozygosity in the development of guidelines for genetic testing of patients with parkinsonism, for the counselling of mutation carriers, and for a better understanding of disease pathogenesis.

Section snippets

Monogenic forms of parkinsonism

Six genes associated with parkinsonism were localised after linkage analysis in large families: mutations have been identified in SNCA (α-synuclein; also known as PARK1),5 parkin,6 PINK1,7 DJ1 (also known as PARK7),8 LRRK2,9, 10 and ATP13A2 (ATPase type 13A2; also known as PARK9).11 Although the identification of dominantly inherited mutations in SNCA, the first gene to be associated with heritable parkinsonism, have revolutionised our understanding of the causes of this disorder and have given

Mutations and mechanisms

LRRK2 was identified in 2004 by two independent groups,9, 10 and LRRK2 mutations are now recognised as the most common cause of genetic parkinsonism. Mutations in LRRK2 are mostly, but not exclusively,22, 32, 34 associated with a classic parkinsonism-like phenotype with onset at age 50–70 years.33, 35, 36 LRRK2 is a large gene of 51 exons; it encodes the 2527-aminoacid-residue protein LRRK2 (also known as dardarin), which contains various conserved domains.9, 10 There are more than 50 variants

Mutations and mechanisms

Homozygous or compound heterozygous mutations in the recessive parkinsonism genes parkin and PINK1 are unequivocally associated with heritable parkinsonism and early age at onset. However, penetrance might be reduced in isolated cases, as suggested by a recent report of a neurologically unaffected carrier of a compound heterozygous parkin mutation at age 56 years;59 alternatively, penetrance in recessive genes might be age dependent, and expression of the parkinsonism phenotype might simply be

Statement of hypothesis

Like many ageing-associated conditions, such as coronary heart disease and Alzheimer's disease, classic parkinsonism is a complex disorder. As such, it encompasses a syndrome that has numerous causes. Different genes by themselves, alleles working in synergy, or genetic traits together with environmental contributors can produce highly similar phenotypes (ie, phenocopies). According to this model, cumulative genetic and environmental factors of greater severity will result in onset of the

Future perspectives

Irrespective of the allele in question or the mode of its inheritance, the penetrance and expressivity of heterozygous gene mutations have far-reaching implications for patient care and Parkinson's disease research alike. First, techniques for clinical and laboratory screening of patients and controls need to be improved. In the clinical setting, particular emphasis should be placed on minor motor signs; rating scales might need to be adapted (or newly designed) to represent subtle changes in

References (125)

  • MB Feany et al.

    Parkin: a multipurpose neuroprotective agent?

    Neuron

    (2003)
  • JJ Palacino et al.

    Mitochondrial dysfunction and oxidative damage in parkin-deficient mice

    J Biol Chem

    (2004)
  • A Petit et al.

    Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations

    J Biol Chem

    (2005)
  • C Klein et al.

    The genetics of Parkinson disease

    Nat Clinl Pract Neurol

    (2006)
  • CB Lucking et al.

    Association between early-onset Parkinson's disease and mutations in the parkin gene

    N Engl J Med

    (2000)
  • S Lesage et al.

    LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs

    N Engl J Med

    (2006)
  • LJ Ozelius et al.

    LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews

    N Engl J Med

    (2006)
  • MH Polymeropoulos et al.

    Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

    Science

    (1997)
  • T Kitada et al.

    Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

    Nature

    (1998)
  • EM Valente et al.

    Hereditary early-onset Parkinson's disease caused by mutations in PINK1

    Science

    (2004)
  • V Bonifati et al.

    DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism

    Neurol Sci

    (2003)
  • A Ramirez et al.

    Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase

    Nat Genet

    (2006)
  • MG Spillantini et al.

    Alpha-synuclein in Lewy bodies

    Nature

    (1997)
  • WR Galpern et al.

    Interface between tauopathies and synucleinopathies: a tale of two proteins

    Ann Neurol

    (2006)
  • D Berg et al.

    Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients

    Mov Disord

    (2005)
  • C Klein et al.

    PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism

    Eur J Hum Genet

    (2005)
  • A Abeliovich et al.

    Parkinsonism genes: culprits and clues

    J Neurochem

    (2006)
  • DM Kay et al.

    Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation

    Mov Disord

    (2005)
  • A Carmine Belin et al.

    Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian

    Mov Disord

    (2006)
  • Y Hatano et al.

    Novel PINK1 mutations in early-onset parkinsonism

    Ann Neurol

    (2004)
  • S Goldwurm et al.

    The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor

    J Med Genet

    (2005)
  • K Hedrich et al.

    Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit?

    Arch Neurol

    (2006)
  • IF Mata et al.

    Lrrk2 pathogenic substitutions in Parkinson's disease

    Neurogenetics

    (2005)
  • CE Mamah et al.

    Interaction of alpha-synuclein and tau genotypes in Parkinson's disease

    Ann Neurol

    (2005)
  • DM Maraganore et al.

    UCHL1 is a Parkinson's disease susceptibility gene

    Ann Neurol

    (2004)
  • EK Tan et al.

    The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence

    Hum Genet

    (2006)
  • A McInerney-Leo et al.

    Genetic testing in Parkinson's disease

    Mov Disord

    (2005)
  • E Lohmann et al.

    How much phenotypic variation can be attributed to parkin genotype?

    Ann Neurol

    (2003)
  • CP Zabetian et al.

    A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations

    Neurology

    (2005)
  • DM Kay et al.

    Parkinson's disease and LRRK2: frequency of a common mutation in US movement disorder clinics

    Mov Disord

    (2006)
  • L Ishihara et al.

    Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations

    Arch Neurol

    (2006)
  • K Hedrich et al.

    Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease

    Mov Disord

    (2006)
  • D Civitelli et al.

    LRRK2 G6055A mutation in Italian patients with familial or sporadic Parkinson's disease

    Clin Genet

    (2007)
  • JJ Ferreira et al.

    High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal

    Mov Disord

    (2007)
  • M Funayama et al.

    An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family

    Ann Neurol

    (2005)
  • M Farrer et al.

    LRRK2 mutations in Parkinson disease

    Neurology

    (2005)
  • C Paisan-Ruiz et al.

    LRRK2 gene in Parkinson disease: mutation analysis and case control association study

    Neurology

    (2005)
  • S Lesage et al.

    G2019S LRRK2 mutation in French and North African families with Parkinson's disease

    Ann Neurol

    (2005)
  • D Berg et al.

    Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*

    Brain

    (2005)
  • A Di Fonzo et al.

    Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease

    Eur J Hum Genet

    (2006)
  • Cited by (247)

    View all citing articles on Scopus
    View full text